Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jul 22 2022

Full Issue

Pfizer's Covid Shots Prove Effective At Keeping Kids Out Of Hospital

Two doses of Pfizer's covid vaccine were 82.7% effective at preventing hospitalizations among 5- to 11-year olds. Separately, an experimental oral covid vaccine is reportedly showing promise, and a Gates Foundation study found existing boosters were surprisingly good against BA.5.

CIDRAP: Pfizer Vaccine 83% Effective Against Hospital Omicron Illness In Kids 5 To 11

In 5- to 11-year-old children, two doses of the Pfizer/BioNTech COVID-19 vaccine were 36.8% effective in preventing all SARS-CoV-2 infections, 63.5% against test-confirmed cases, and 82.7% against hospitalization amid the Omicron variant surge in Singapore, finds a real-world study published yesterday in the New England Journal of Medicine (NEJM). (7/21)

Reuters: Oral Vaccine Shows Promise

An experimental COVID-19 vaccine in the form of an oral tablet has shown promising immune responses in a small preliminary trial designed mainly to evaluate its safety, according to drug manufacturer Vaxart Inc (VXRT.O). The South San Francisco, California-based company had earlier said the tablet was well tolerated, with no one dropping out of the study because of adverse effects. On Tuesday, they reported on immune responses in the 35 healthy volunteers who received the tablet. (Lapid, 7/21)

Fortune: Bill & Melinda Gates Foundation Partly Funded A Study About COVID-19 Booster Shots For The BA.5 Omicron Subvariant. Surprise: Boosters Still Work

Getting a booster can generate enough of an antibody response and protection from severe disease outcomes to hold up against any of the new Omicron subvariants, according to an early release paper published this week in Science. That extends to BA.5, now the most prevalent COVID strain in the U.S. and a driver of COVID-19 reinfections across the country. (Mui, 7/21)

CIDRAP: In COVID-19 Omicron Patients, High Blood Pressure Doubles Risk Of Hospitalization

People who have high blood pressure and Omicron-variant COVID-19 are at more than double the risk for hospitalization—even if they received three mRNA vaccine doses, according to a single-center study published yesterday in Hypertension. (Van Beusekom, 7/21)

CIDRAP: COVID-19 In Third Trimester—But Not Earlier—Linked To Preterm Birth

A new study of more than 5,000 women shows that contracting COVID-19 during the third trimester of pregnancy is linked to a more than double increased risk of preterm birth. The study was published yesterday in PLOS One. (7/21)

On non-covid research developments —

Stat: AI Shows Potential To Reduce Sepsis Deaths In Real-World Studies

Three studies published Thursday found that an AI platform developed by Bayesian Health and Johns Hopkins University reduced deaths from sepsis by 18.2% in real-world use when physicians responded promptly to its alerts, a finding that suggests AI has potential to become an important tool in battling a leading cause of deaths in hospitals. (Muthukumar, 7/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF